Literature DB >> 30519773

Iftikhar and Colleagues Reply: Methodology Clarified.

Imran H Iftikhar1, Mathew Schimmel2, William Bender2, Colin Swenson2, David Amrol3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30519773     DOI： 10.1007/s00408-018-0185-8

Source DB:  PubMed          Journal:  Lung        ISSN： 0341-2040            Impact factor:   2.584


× No keyword cloud information.
  9 in total

1.  Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

Authors:  Nicola A Hanania; Phillip Korenblat; Kenneth R Chapman; Eric D Bateman; Petr Kopecky; Pierluigi Paggiaro; Akihito Yokoyama; Julie Olsson; Sarah Gray; Cecile T J Holweg; Mark Eisner; Charles Asare; Saloumeh K Fischer; Kun Peng; Wendy S Putnam; John G Matthews
Journal:  Lancet Respir Med       Date:  2016-09-05       Impact factor: 30.700

2.  Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

Authors:  Parameswaran Nair; Sally Wenzel; Klaus F Rabe; Arnaud Bourdin; Njira L Lugogo; Piotr Kuna; Peter Barker; Stephanie Sproule; Sandhia Ponnarambil; Mitchell Goldman
Journal:  N Engl J Med       Date:  2017-05-22       Impact factor: 91.245

3.  Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

Authors:  Klaus F Rabe; Parameswaran Nair; Guy Brusselle; Jorge F Maspero; Mario Castro; Lawrence Sher; Hongjie Zhu; Jennifer D Hamilton; Brian N Swanson; Asif Khan; Jingdong Chao; Heribert Staudinger; Gianluca Pirozzi; Christian Antoni; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Neil M H Graham; Neil Stahl; George D Yancopoulos; Ariel Teper
Journal:  N Engl J Med       Date:  2018-05-21       Impact factor: 91.245

4.  Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Authors:  Mario Castro; Jonathan Corren; Ian D Pavord; Jorge Maspero; Sally Wenzel; Klaus F Rabe; William W Busse; Linda Ford; Lawrence Sher; J Mark FitzGerald; Constance Katelaris; Yuji Tohda; Bingzhi Zhang; Heribert Staudinger; Gianluca Pirozzi; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Asif Khan; Jingdong Chao; Renata Martincova; Neil M H Graham; Jennifer D Hamilton; Brian N Swanson; Neil Stahl; George D Yancopoulos; Ariel Teper
Journal:  N Engl J Med       Date:  2018-05-21       Impact factor: 91.245

5.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

Authors:  Mario Castro; James Zangrilli; Michael E Wechsler; Eric D Bateman; Guy G Brusselle; Philip Bardin; Kevin Murphy; Jorge F Maspero; Christopher O'Brien; Stephanie Korn
Journal:  Lancet Respir Med       Date:  2015-02-23       Impact factor: 30.700

6.  Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.

Authors:  Geoffrey L Chupp; Eric S Bradford; Frank C Albers; Daniel J Bratton; Jie Wang-Jairaj; Linda M Nelsen; Jennifer L Trevor; Antoine Magnan; Anneke Ten Brinke
Journal:  Lancet Respir Med       Date:  2017-04-05       Impact factor: 30.700

7.  Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.

Authors:  Imran H Iftikhar; Mathew Schimmel; William Bender; Colin Swenson; David Amrol
Journal:  Lung       Date:  2018-08-23       Impact factor: 2.584

8.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

9.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.